Abstract:Lysophosphatidic acid (LPA, 1- or 2-acyl-sn-glycerol 3-phosphate) displays an intriguing cell biology that is mediated via interactions with seven-transmembrane G-protein-coupled receptors (GPCRs) and the nuclear hormone receptor PPARγ. To identify receptor-selective LPA analogues, we describe a series of fluorinated LPA analogues in which either the sn-1 or sn-2 hydroxyl group was replaced by a fluoro or fluoromethyl substituent. We also describe stabilized phosphonate analogues in which the bridging oxygen of the monophosphate was replaced by an α-monofluoromethylene (−CHF−) or α-difluoromethylene (−CF2−) moiety. The sn-2- and sn-1-fluoro-LPA analogues were unable to undergo acyl migration, effectively “freezing” them in the sn-1-O-acyl or sn-2-O-acyl forms, respectively. We first tested these LPA analogues on insect Sf9 cells induced to express human LPA1, LPA2, and LPA3 receptors. While none of the analogues were found to be more potent than 1-oleoyl-LPA at LPA1 and LPA2, several LPA analogues were potent LPA3-selective agonists. In contrast, 1-oleoyl-LPA had similar activity at all three receptors. The α-fluoromethylene phosphonate analogue 15 activated calcium release in LPA3-transfected insect Sf9 cells at a concentration 100-fold lower than that of 1-oleoyl-LPA. This activation was enantioselective, with the (2S)-enantiomer showing 1000-fold more activity than the (2R)-enantiomer. Similar results were found for calcium release in HT-29 and OVCAR8 cells. Analogue 15 was also more effective than 1-oleoyl-LPA in activating MAPK and AKT in cells expressing high levels of LPA3. The α-fluoromethylene phosphonate moiety greatly increased the half-life of 15 in cell culture. Thus, α-fluoromethylene LPA analogues are unique new phosphatase-resistant ligands that provide enantiospecific and receptor-specific biological readouts.

Structure−Activity Relationships of Fluorinated Lysophosphatidic Acid Analogues

Elucidating the Binding Mechanism of LPA Species and Analogs in an LPA4 Receptor Homology Model

Toward the Three-Dimensional Structure and Lysophosphatidic Acid Binding Characteristics of the LPA(4)/p2y(9)/GPR23 Receptor: a Homology Modeling Study.

Synthesis and Biological Evaluation of Lysophosphatidic Acid Analogues Using Conformational Restriction and Bioisosteric Replacement Strategies

Structural mechanisms of potent lysophosphatidic acid receptor 1 activation by nonlipid basic agonists

Switching Lysophosphatidylserine G Protein-Coupled Receptor Agonists to Antagonists by Acylation of the Hydrophilic Serine Amine

LPA3: Pharmacodynamic differences between lysophosphatidic acid and oleoyl-methoxy glycerophosphothionate. Biased agonism, two sites.

Design, Synthesis, and in Vitro Bioactivity Evaluation of Fluorine-Containing Analogues for Sphingosine-1-phosphate 2 Receptor.

Exploration of LPS2 agonist binding modes using the combination of a new hydrophobic scaffold and homology modeling

Crystal structures and biochemical studies of human lysophosphatidic acid phosphatase type 6

Crystal structures and biochemical studies of human lysophosphatidic acid phosphatase type 6 ESEARCH ARTICLER

Characterization of Lysophospholipase D Activity in Mammalian Cell Membranes

Discovery of a Novel Orally Active, Selective LPA Receptor Type 1 Antagonist, 4-(4-(2-Isopropylphenyl)-4-((2-methoxy-4-methylphenyl)carbamoyl)piperidin-1-yl)-4-oxobutanoic Acid, with a Distinct Molecular Scaffold

Isoquinolone derivatives as lysophosphatidic acid receptor 5 (LPA5) antagonists: Investigation of structure-activity relationships, ADME properties and analgesic effects

Phosphonic Acid Analogs of Fluorophenylalanines as Inhibitors of Human and Porcine Aminopeptidases N: Validation of the Importance of the Substitution of the Aromatic Ring

Mitogenic action of lysophosphatidic acid and phosphatidic acid on fibroblasts. Dependence on acyl-chain length and inhibition by suramin

Lysophosphatidic acid and its receptors: pharmacology and therapeutic potential in atherosclerosis and vascular disease

Lysophospholipid receptors in drug discovery

Structural determinants of blockade of eosinophil activation, adhesion and secretion by synthetic analogs of phomactin.

LPA3 receptors have orthosteric and allosteric binding sites evidenced under docking studies.

Differential activation mechanisms of lipid GPCRs by lysophosphatidic acid and sphingosine 1-phosphate